PL3348557T3 - Imidazo[1,2-a]pirydyny do leczenia lub zapobiegania hiperurikemii lub dnie moczanowej - Google Patents

Imidazo[1,2-a]pirydyny do leczenia lub zapobiegania hiperurikemii lub dnie moczanowej

Info

Publication number
PL3348557T3
PL3348557T3 PL16843670T PL16843670T PL3348557T3 PL 3348557 T3 PL3348557 T3 PL 3348557T3 PL 16843670 T PL16843670 T PL 16843670T PL 16843670 T PL16843670 T PL 16843670T PL 3348557 T3 PL3348557 T3 PL 3348557T3
Authority
PL
Poland
Prior art keywords
gout
pyridines
imidazo
treating
preventing hyperuricemia
Prior art date
Application number
PL16843670T
Other languages
English (en)
Inventor
Dongfang Shi
Changjin FU
Xi CHENG
Jianghua Zhu
Jie Wen
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd
Publication of PL3348557T3 publication Critical patent/PL3348557T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16843670T 2015-09-10 2016-09-08 Imidazo[1,2-a]pirydyny do leczenia lub zapobiegania hiperurikemii lub dnie moczanowej PL3348557T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
EP16843670.7A EP3348557B1 (en) 2015-09-10 2016-09-08 Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout
PCT/CN2016/098468 WO2017041732A1 (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物

Publications (1)

Publication Number Publication Date
PL3348557T3 true PL3348557T3 (pl) 2020-11-16

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16843670T PL3348557T3 (pl) 2015-09-10 2016-09-08 Imidazo[1,2-a]pirydyny do leczenia lub zapobiegania hiperurikemii lub dnie moczanowej

Country Status (27)

Country Link
US (1) US10399971B2 (pl)
EP (1) EP3348557B1 (pl)
JP (1) JP6635527B2 (pl)
KR (1) KR102109061B1 (pl)
CN (1) CN106432229B (pl)
AU (1) AU2016320073B2 (pl)
BR (1) BR112018004863B1 (pl)
CA (1) CA2998034C (pl)
CY (1) CY1123137T1 (pl)
DK (1) DK3348557T3 (pl)
EA (1) EA037280B1 (pl)
ES (1) ES2803223T3 (pl)
HR (1) HRP20201094T1 (pl)
HU (1) HUE051448T2 (pl)
IL (1) IL257960A (pl)
LT (1) LT3348557T (pl)
MX (1) MX375068B (pl)
MY (1) MY195675A (pl)
NZ (1) NZ741318A (pl)
PL (1) PL3348557T3 (pl)
PT (1) PT3348557T (pl)
RS (1) RS60697B1 (pl)
SG (1) SG11201802010QA (pl)
SI (1) SI3348557T1 (pl)
TW (1) TWI681772B (pl)
WO (1) WO2017041732A1 (pl)
ZA (1) ZA201802312B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
JP6915907B2 (ja) * 2017-05-26 2021-08-04 江▲蘇▼新元素医▲薬▼科技有限公司Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. 尿酸排泄を促進するurat1阻害剤
CN114213331B (zh) * 2017-05-26 2024-06-21 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
US11453674B2 (en) 2018-01-19 2022-09-27 Evopoint Biosciences Co., Ltd. Heterocyclic compound, preparation method and use thereof in medicine
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN113717072A (zh) * 2021-09-28 2021-11-30 铜仁百朗制药有限公司 一种治疗便秘药物中间体的制备方法
WO2023208108A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout
TWI898321B (zh) * 2023-11-17 2025-09-21 大陸商杭州新元素藥業有限公司 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2025237171A1 (zh) * 2024-05-11 2025-11-20 广州市联瑞制药有限公司 嘧啶并五元氮杂环酚类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
JP5844376B2 (ja) * 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発:それらの尿酸排泄効果のために設計された化合物
DK3444238T3 (da) * 2012-07-27 2022-01-03 Sato Pharma Fremgangsmåde til fremstilling af difluormethylenforbindelser

Also Published As

Publication number Publication date
JP2018526417A (ja) 2018-09-13
SI3348557T1 (sl) 2020-09-30
US20180282321A1 (en) 2018-10-04
KR102109061B1 (ko) 2020-05-11
LT3348557T (lt) 2020-08-10
EP3348557B1 (en) 2020-04-29
BR112018004863B1 (pt) 2023-04-18
CN106432229B (zh) 2018-01-12
CA2998034C (en) 2021-05-04
NZ741318A (en) 2019-03-29
AU2016320073B2 (en) 2019-05-09
MX2018003006A (es) 2018-08-09
ZA201802312B (en) 2024-11-27
PT3348557T (pt) 2020-08-03
TW201808284A (zh) 2018-03-16
EA037280B1 (ru) 2021-03-03
MY195675A (en) 2023-02-03
CN106432229A (zh) 2017-02-22
RS60697B1 (sr) 2020-09-30
MX375068B (es) 2025-03-06
ES2803223T3 (es) 2021-01-25
DK3348557T3 (da) 2020-07-20
EP3348557A4 (en) 2019-03-06
HRP20201094T1 (hr) 2020-10-30
KR20180044426A (ko) 2018-05-02
EA201890694A1 (ru) 2018-10-31
EP3348557A1 (en) 2018-07-18
WO2017041732A1 (zh) 2017-03-16
BR112018004863A2 (pl) 2018-10-02
US10399971B2 (en) 2019-09-03
CA2998034A1 (en) 2017-03-16
HUE051448T2 (hu) 2021-03-01
TWI681772B (zh) 2020-01-11
SG11201802010QA (en) 2018-04-27
CY1123137T1 (el) 2021-10-29
JP6635527B2 (ja) 2020-01-29
IL257960A (en) 2018-05-31
AU2016320073A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
LT3348557T (lt) Imidazo[1,2a]piridinai, skirti hiperurikemijos arba podagros gydymui arba prevencijai
IL256501B (en) Causes, uses and methods of treating synuclein pathology
PL3257853T3 (pl) Skondensowany związek heterocykliczny i środek zwalczający szkodliwe organizmy
IL251164A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
PT3484862T (pt) Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
GB2567616B (en) Treatment method
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
HUE071527T2 (hu) Tradipitant gasztroparézis kezelésében történõ alkalmazásra
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
GB2571601B (en) Treatment method
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
SG11202001806TA (en) Treatment method
ZA201907975B (en) Agent for preventing or treating tauopathy
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
IL251166A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
GB201514303D0 (en) Bifidobacteria for treating cardiac conditions
GB201514302D0 (en) Lactobacilli for treating cardiac dysfunction
EP3246432A4 (en) Method for treating parts